thebiostories

Phase 1 Clinical Trials of MK-7602: A Promising New Chapter in the Fight Against Malaria ⏱ In 30 Seconds ✓ MK-7602 is a first-in-class experimental antimalarial drug jointly developed by WEHI and MSD . ✓ It blocks two essential malaria parasite enzymes, plasmepsin IX and plasmepsin X . ✓ Phase 1 studies found that MK-7602 was generally well tolerated in healthy volunteers and reached blood concentrations predicted to have antimalarial activity. ✓ The results mark an important transition from nearly a decade of laboratory research to early clinical development. From Laboratory Discovery to Human Trials For decades, malaria parasites have repeatedly evolved resistance to medicines that once transformed global malaria control, creating an urgent need for drugs that attack the parasite through entirely different biological mechanisms. In March 2026, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) reported an important milestone in...

🌏 Available in: English | 한국어 An Australian Discovery Reveals a Dysregulated Immune Pathway in Acute Rheumatic Fever How a common bacterial infection can trigger persistent inflammation and lifelong heart-valve damage ⏱ In 30 Seconds ✓ Acute rheumatic fever can develop after infection with Group A Streptococcus and may eventually cause permanent heart-valve damage. ✓ Australian researchers identified a dysregulated IL-1β–GM-CSF immune pathway in cells from people with acute rheumatic fever. ✓ IL-1β promoted the expansion of inflammatory GM-CSF-producing CD4 T cells , offering a possible explanation for persistent immune activation. ✓ The study also showed that hydroxychloroquine could suppress this response in laboratory experiments, suggesting a potential direction for future immune-targeted therapies. Every year, hundreds of millions of people are infected with Group A Streptococcus , commonly known as GAS. For most people, the infection causes a...

🌏 Available in: English | 한국어 Peter Doherty and the Theory That Made It All Make Sense ⏱ In 30 Seconds ✓ Peter Doherty and Rolf Zinkernagel discovered that killer T cells recognise virus-infected cells only when viral antigens are presented together with the body’s own MHC molecules . ✓ This phenomenon, known as MHC restriction , explained why T cells respond to a precise combination of infection and self. ✓ The discovery built naturally on Frank Macfarlane Burnet’s clonal selection theory , which proposed that immune responses arise through the selection and expansion of specific lymphocyte clones. ✓ Doherty and Zinkernagel shared the 1996 Nobel Prize in Physiology or Medicine for revealing how the immune system recognises virus-infected cells. For years, I knew clonal selection and MHC restriction as two fundamental concepts in immunology. Like many things we learn in science, however, I tended to think of them separately. It was only when I loo...